Cardio-cerebrovascular Disease

Models of Pulmonary Arterial Hypertension

Greentech Bioscience offers monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) rat model for efficient drug efficacy testing. Based on our experienced pharmacology and pharmacodynamics team and validated animal model library, we ensure reliable and reproducible data.

Rat Model of Pulmonary Arterial Hypertension

Monocrotaline-treated rats are frequently used in the preclinical studies of anti-PAH drugs. Monocrotaline cause pulmonary vascular remodeling and increased vascular resistance, ultimately leading to heart failure.

Induction: pulmonary vascular endothelium can be selectively damaged by intraperitoneal or subcutaneous injection of MCT, leading to PAH after 3~4 weeks.

Species: rats

Disease characteristics: monocrotaline-induced PAH in rats are similar with human PAH in hemodynamics and histopathology. MCT that causes endothelial dysfunction can mimic human PAH with inflammatory conditions, but hardly PAH associated with severe angiogenesis.

Clinical Assessment

Right ventricular systolic pressure (RVSP)

Right ventricular hypertrophy index (RVHI)

Pulmonary vascular remodeling

Basic Service

Body weight, food intake, excretion

Blood and tissue collection




Request a quote now, or email us at to inquire about our services or obtain a quote for your project.


1. Kimura S, et al. Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension. 2009 May;53(5):877-83.

2. Peiran Yang, et al. A novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertension. Br J Pharmacol.2019 May;176(9):1206-1221.